Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support services; Warehousing, including dedicated storage, shared warehouses, packing and value-added services, such as labeling and products assembly; Logistics systems, including software for logistics management; Passenger transportation, including transportation of personnel and students; Special services, including rental of bus and vans; Moving, including national and international moving services, and Advertising, including custom transportation services during marketing campaigns. The Company operates through a number of group companies.


PINL:GRPOF - Post by User

Post by Davesnothereon Jan 28, 2021 7:56am
179 Views
Post# 32407308

New Financing - no surprise

New Financing - no surprise
etra Bio-Pharma Inc. Announces a Non-Brokered Private Placement

 

27 Jan 202122:14 ET  

CNW Group

 

Tetra Bio-Pharma Inc. ("Tetra Bio-Pharma" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that it is conducting a non-brokered private placement of 11,141,176 units of the Company (collectively, the "Units") at a price of C$0.17 per Unit for aggregate gross proceeds of approximately $1,900,000 (the "Offering").

This Offering is being conducted with a group of strategic investors including Dr. Michael Nashat, PharmD, a co-founder and the former President and Chief Executive Officer of TerrAscend Corp. Dr. Nashat is also the co-founder of OnPharm Independent Pharmacy Group, one of the largest independent non-banner group in Canada and the managing partner of RxInfinity Inc.

Each Unit will consist of one common share of the Company (each, a "Common Share") and one common share purchase warrant of the Company (each, a "Warrant"). Each Warrant will entitle the holder thereof to acquire, on payment of C$0.21 to the Company, one common share of the Company (each, a "Warrant Share"), subject to adjustment in certain circumstances, for a period of 24 months from the closing date. The Warrants are subject to acceleration, at the Company's discretion, in the event the volume-weighted average closing price of the Common Shares on the Toronto Stock Exchange is equal to or greater than C$0.60 for a period of 10 consecutive trading days.

The Offering is expected to close on or about January 29, 2021.


<< Previous
Bullboard Posts
Next >>
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse